Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
MEDICA: With over 4,500 exhibitors from 66 countries and more than 81,000 visitors from all over the world, MEDICA in Düsseldorf is one of the largest medical B2B trade fairs in the world. A wide range of innovative products and services from the fields of medical imaging, laboratory technology, diagnostics, health IT, mobile health as well as physiotherapy/orthopaedic technology and medical consumables are presented here. The extensive programme of first-class forums, conferences and special shows provides opportunities for interesting presentations and discussions with experts and politicians and also includes pitches of new products and award ceremonies
Does anyone know how much is the cost of Genedrive® CYP2C19 test?
70p (Nice full approval and sales)
Where is our sub 10p buyer friend? Lol 😂 Please keep buying until sales or NICE news 😂
No RNS :-(
System: I think it is a sell. The mid-price was 10.25.
Dr Sheena Meredith | Disclosures | 18 September 2023
A revolutionary point-of-care testing device that could help to prevent recurrent strokes could soon be rolled out across the NHS, according to researchers at the University of Manchester. The shoebox-sized device enables bedside testing using a cheek swab to detect genetic changes that reduce the effectiveness of clopidogrel, the current first line preventive treatment, so that alternative antiplatelet therapy can be prescribed.
3x10ks were buys?????
I am sure someone posted on this board that the company reassured in an email reply that sales were happening in the background but it was not confirmed through RNS. So most likely it was a lie from Budd?????.
Nissan: Is the share price going to be 50p or at least 30p today? Still no news from the NICE committee meeting, - today is the last day of your prediction lol
What is -100k trade mean? There are two 100k shares trades. Experts opinion please
Copy and paste from bigAI67 message:
For your consideration:-
As of 14th March 2023 we had £2 mil in cash + £2 Mil from RF in April + No less than £500k R&D Tax refund due end of this year 2023 = £4,500,000
Since April we have also received a further £600,000 from RF (And a further £336,000 is due from RF on exercise of their first two drawdowns of Warrants – Date unknown?)
So £4,500,000 + £600,000 (Drawdown money from RF) = £5,100,000
Should we receive £2,100,000 DEVOTE Funding then we are looking at £7,200,000, which takes Our Financial status forward 18 Months Funding from March 14th 2023 = 14th September 2024.
Note: - Although DEVOTE funding of £2,100,000 may not be paid to Our Genedrive in a cash lump sum - it would reduce Our monthly outgoing £400k costs, which I believe may be already reducing our CYP2C19 development costs by as much as £125,000 per month. This saving is effectively keeping cash in the bank!!
Then - If we conservatively add in a further £1,000,000 Tax Development Refund for the period Jan 2023 to end of June 2024 – Takes Our Finances to £8,200,000 = 30th November 2024.
I believe we will receive a further £2,400,000 Drawdown money (8 x £300,000) from RF – Should this be so - Then we are looking at Funding well into 2025 !!
Along this Financial road, we will be receiving revenue from AIHL and CYP2C19 sales - to add in !!!
From Our GDR - DEVOTE Funding - ‘’to further the ‘validation’ and ‘implementation’ of the new Genedrive® CYP2C19 ID Kit pharmacogenetic test in a time critical clinical setting’’ = ‘'Validation’ and ‘Implementation’'
AIMVHO !!!
Was the 200k trade a sell or a buy? I think it was a sell - the mid-price was 11.75 so it could be a sell.
Lol 😂 Guy
I put 67k Slacker, averaging 25p. :-(
Big buy this morning. Looking good!
The Jefferies London Healthcare Conference is the largest healthcare-dedicated conference in Europe. Our conference will again feature leading public and private companies from the pharmaceuticals, biotechnology, medical technology, and healthcare services sectors from the Americas, Europe, Middle East, Africa, Asia, and Australia.
I strongly feel that the new CEO will give us good news before NICE full recommendation in December. I am sure I will be criticised for saying this, but he has good experience selling products that Bud lacked. The share price is in an oversold territory and a slight bounce is imminent on a technical basis. Three months are very important for the company and we will hear good news by then.
Looking good???? Which screen you are looking at? Only 9 trades so far and no big buys
BigAl67: I have saved your post-re-GDR finance . I was thinking of re-posting it. thank you.